Effect of dipyridamole plus aspirin on hemodialysis graft patency

New England Journal of Medicine

Volumn 360, Issue 21, 2009, Pages 2191-2201

  Dixon, Bradley S ^a,s   Beck, Gerald J ^b   Vazquez, Miguel A ^c   Greenberg, Arthur ^f   Delmez, James A ^g   Allon, Michael ⁱ   Dember, Laura M ^j   Himmelfarb, Jonathan ^k   Gassman, Jennifer J ^b   Greene, Tom ^l   Radeva, Milena K ^b   Davidson, Ingemar J ^c   Ikizler, T Alp ^m   Braden, Gregory L ⁿ   Fenves, Andrew Z ^d   Kaufman, James S ^j   Cotton Jr , James R ^e   Martin, Kevin J ^h   McNeil, James W ^o   Rahman, Asif ^p   Lawson, Jeffery H ^f   Whiting, James F ^k   Hu, Bo ^b   Meyers, Catherine M ^q   Kusek, John W ^q   Feldman, Harold I ^r   more..

^a UNIVERSITY OF IOWA   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^e Tyler Nephrology Associates   (United States)

^f DUKE UNIVERSITY   (United States)

^g WASHINGTON UNIVERSITY   (United States)

^h SAINT LOUIS UNIVERSITY   (United States)

ⁱ UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^j BOSTON UNIVERSITY   (United States)

^k MAINE MEDICAL CENTER   (United States)

^l UNIVERSITY OF UTAH   (United States)

^m VANDERBILT UNIVERSITY   (United States)

ⁿ BAYSTATE MEDICAL CENTER   (United States)

^o Vascular Surgery Associates   (United States)

^p CHARLESTON AREA MEDICAL CENTER   (United States)

^q NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^r UNIVERSITY OF PENNSYLVANIA   (United States)

^s UNIVERSITY OF IOWA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; DIPYRIDAMOLE; PLACEBO; ANTITHROMBOCYTIC AGENT;

ADULT; ARTERIOVENOUS SHUNT; ARTICLE; BLEEDING; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG FATALITY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GRAFT FAILURE; GRAFT PATENCY; HEART ARRHYTHMIA; HEMODIALYSIS; HUMAN; INCIDENCE; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STENOSIS; TREATMENT DURATION; UNITED STATES; DELAYED RELEASE FORMULATION; DRUG COMBINATION; GRAFT OCCLUSION; KAPLAN MEIER METHOD; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL; RENAL REPLACEMENT THERAPY; THROMBOSIS;

ASPIRIN; DELAYED-ACTION PREPARATIONS; DIPYRIDAMOLE; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; GRAFT OCCLUSION, VASCULAR; HUMANS; INCIDENCE; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; PROPORTIONAL HAZARDS MODELS; RENAL DIALYSIS; THROMBOSIS;

EID: 66149118225     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa0805840     Document Type: Article

References (34)

1. Feldman HI, Kobrin S, Wasserstein A. Hemodialysis vascular access morbidity. J Am Soc Nephrol 1996;7:523-535
2. U.S. Renal Data System. 2006 Annual data report: atlas of end-stage renal disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2006.
3. Roy-Chaudhury P, Sukhatme VP, Cheung AK. Hemodialysis vascular access dysfunction: a cellular and molecular viewpoint. J Am Soc Nephrol 2006;17:1112-1127
4. Gibson KD, Gillen DL, Caps MT, Kohler TR, Sherrard DJ, Stehman-Breen CO. Vascular access survival and incidence of revisions: a comparison of prosthetic grafts, simple autogenous fistulas, and venous transposition fistulas from the United States Renal Data System Dialysis Morbidity and Mortality Study. J Vasc Surg 2001;34:694-700. (Pubitemid 33664921)
5. U.S. Renal Data System. 2007 Annual data report: atlas of end-stage renal disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2007.
6. Sreedhara R, Himmelfarb J, Lazarus JM, Hakim RM. Anti-platelet therapy in graft thrombosis: results of a prospective, randomized, double-blind study. Kidney Int 1994;45:1477-1483 (Pubitemid 24135036)
7. Dubey RK, Gillespie DG, Mi Z, Jackson EK. Adenosine inhibits growth of human aortic smooth muscle cells via A2B receptors. Hypertension 1998;31:516-521 (Pubitemid 28124768)
8. Ingerman-Wojenski CM, Silver MJ. Model system to study interaction of platelets with damaged arterial wall. II. Inhibition of smooth muscle cell proliferation by dipyridamole and AH-P719. Exp Mol Pathol 1988;48:116-134
9. Singh JP, Rothfuss KJ, Wiernicki TR, et al. Dipyridamole directly inhibits vascular smooth muscle cell proliferation in vitro and in vivo: implications in the treatment of restenosis after angioplasty. J Am Coll Cardiol 1994;23:665-671 (Pubitemid 24074945)
10. Faxon DP, Sanborn TA, Haudenschild CC, Ryan TJ. Effect of antiplatelet therapy on restenosis after experimental angioplasty. Am J Cardiol 1984;53:72C-76C. (Pubitemid 14075392)
11. Chesebro JH, Fuster V, Elveback LR, et al. Effect of dipyridamole and aspirin on late vein-graft patency after coronary bypass operations. N Engl J Med 1984;310:209-214 (Pubitemid 14221958)
12. Hess H, Mietaschk A, Deichsel G. Drug-induced inhibition of platelet function delays progression of peripheral occlusive arterial disease: a prospective double-blind arteriographically controlled trial. Lancet 1985;1:415-419 (Pubitemid 15173130)
13. Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A. European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996;143:1-13.
14. Dixon BS, Beck GJ, Dember LM, et al. Design of the Dialysis Access Consortium (DAC) Aggrenox Prevention of Access Stenosis Trial. Clin Trials 2005;2:400-412 (Pubitemid 41586025)
15. Depner TA, Krivitski NM. Clinical measurement of blood flow in hemodialysis access fistulae and grafts by ultrasound dilution. ASAIO J 1995;41:M745-M749.
16. Gradzki R, Dhingra RK, Port FK, Roys E, Weitzel WF, Messana JM. Use of ACE inhibitors is associated with prolonged survival of arteriovenous grafts. Am J Kidney Dis 2001;38:1240-1244 (Pubitemid 34193109)
17. Miller PE, Carlton D, Deierhoi MH, Redden DT, Allon M. Natural history of arteriovenous grafts in hemodialysis patients. Am J Kidney Dis 2000;36:68-74. (Pubitemid 30432566)
18. Cinat ME, Hopkins J, Wilson SE. A prospective evaluation of PTFE graft patency and surveillance techniques in hemodialysis access. Ann Vasc Surg 1999;13:191-198 (Pubitemid 29138182)
19. Hodges TC, Fillinger MF, Zwolak RM, Walsh DB, Bech F, Cronenwett JL. Longitudinal comparison of dialysis access methods: risk factors for failure. J Vasc Surg 1997;26:1009-1019 (Pubitemid 28018947)
20. Woods JD, Turenne MN, Strawderman RL, et al. Vascular access survival among incident hemodialysis patients in the United States. Am J Kidney Dis 1997;30:50-57 (Pubitemid 27284374)
21. Eknoyan G, Beck GJ, Cheung AK, et al. Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med 2002;347:2010-2019 (Pubitemid 35461657)
22. Wang SK, Tsiatis AA. Approximately optimal one-parameter boundaries for group sequential trials. Biometrics 1987;43:193-199 (Pubitemid 17063902)
23. Allon M. Current management of vascular access. Clin J Am Soc Nephrol 2007;2:786-800.
24. Himmelfarb J. Chronic kidney disease and the public health: gaps in evidence from interventional trials. JAMA 2007;297:2630-2633 (Pubitemid 46961034)
25. Dörffler-Melly J, Koopman MM, Prins MH, Büller HR. Antiplatelet and anticoagulant drugs for prevention of restenosis/reocclusion following peripheral endovascular treatment. Cochrane Database Syst Rev 2005;1:CD002071.
26. Halkes PH, van Gijn J, Kappelle LJ, Koudstaal PJ, Algra A. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. Lancet 2006;367:1665-1673 [Erratum, Lancet 2007;369:274.]
27. Kaufman JS, O'Connor TZ, Zhang JH, et al. Randomized controlled trial of clopidogrel plus aspirin to prevent hemodialysis access graft thrombosis. J Am Soc Nephrol 2003;14:2313-2321 (Pubitemid 37052378)
28. Crowther MA, Clase CM, Margetts PJ, et al. Low-intensity warfarin is ineffective for the prevention of PTFE graft failure in patients on hemodialysis: a randomized controlled trial. J Am Soc Nephrol 2002;13:2331-2337
29. Saran R, Dykstra DM, Wolfe RA, Gillespie B, Held PJ, Young EW. Association between vascular access failure and the use of specific drugs: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2002;40:1255-1263 (Pubitemid 35403138)
30. Yevzlin AS, Conley EL, Sanchez RJ, Young HN, Becker BN. Vascular access outcomes and medication use: a USRDS study. Semin Dial 2006;19:535-539
31. Xue JL, Dahl D, Ebben JP, Collins AJ. The association of initial hemodialysis access type with mortality outcomes in elderly Medicare ESRD patients. Am J Kidney Dis 2003;42:1013-1019 (Pubitemid 37322918)
32. Reddan D, Klassen P, Frankenfield DL, et al. National profile of practice patterns for hemodialysis vascular access in the United States. J Am Soc Nephrol 2002;13:2117-2124 (Pubitemid 34790789)
33. Dember LM, Beck GJ, Allon M, et al. Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial. JAMA 2008;299:2164-2171
34. Spergel LM, Ravani P, Asif A, Roy-Chaudhury P, Besarab A. Autogenous arteriovenous fistula options. J Nephrol 2007;20:288-298 (Pubitemid 47570358)